SlideShare una empresa de Scribd logo
1 de 4
Descargar para leer sin conexión
Generic Drugs Market in Japan 2015-2019
About Generic Drugs
A generic drug is a duplicate of brand-name drugs and has the same dosage form, active ingredient(s), potency, route of administration, quality, and intended use
as that of branded drugs. Generic drugs enter the market once the patent protection of the original developer expires. Generally, the cost of generic drugs is 50-70
percent lower than that of their brand-name counterparts, while meeting the very same standards of safety, quality, and efficacy as the innovator drugs. Generic
drugs help the manufacturer by eliminating the need to develop and market a new drug. As the patent approaches expiration, manufacturers can apply to the FDA
for approval to manufacture and sell generic versions of the drug. Generic drugs are equal to and within the bioequivalence range of branded drugs.
TechNavio's analysts forecast the Generic Drugs market in Japan to grow at a CAGR of 8.16 percent over the period 2014-2019.
Covered in this Report
The Generic Drugs market in Japan can be divided into three segments: Generic Prescription Medicines, Super Generics, and Biosimilars. This report covers the
present scenario and the growth prospects of the Generic Drugs market in Japan for the period 20152019. To calculate the market size, the report considers the
revenue generated from the following segments:
Generic Prescription Medicines
Super Generics
Biosimilars
TechNavio's report, the Generic Drugs market in Japan 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts.
The report covers the market landscape of the Generic Drugs market in Japan and its growth prospects over the coming years. The report also includes a
discussion of the key vendors operating in this market.
Key Vendors
Meiji Seika Pharma
Nichi-Iko Pharmaceutical
Nipro Pharma
Sawai Pharmaceuticals
Teva Pharmaceutical Industries
Towa Pharmaceutical
Other Prominent Vendors
Actavis
Daiichi Sankyo
Daito Pharmaceutical
Eisai
Fuji Pharma
GlaxoSmithKline
Hikari Pharmaceutical
Hospira
Mylan
Nihon Generic
Nippon Chemipher
Nippon Kayaku
Nissin Pharmaceutical
Ohara Pharmaceutical
Pfizer
Sandoz
Taiyo Yakuhin
Takeda Pharmaceutical
Zensei Pharmaceutical Industries
Market Driver
Increase in Number of Patent Expiries
For a full, detailed list, view our report.
Market Challenge
Intense Competition among Vendors
For a full, detailed list, view our report
Market Trend
Increase in M&A
For a full, detailed list, view our report
Key Questions Answered in this Report
Generic Drugs Market in Japan 2015-2019
What will the market size be in 2019 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List Of Abbreviations
03. Scope Of The Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Country Overview Of Japan
07. Approval Pathway Of Generic Drugs In Japan
07.1 Master File Scheme For Active Ingredients
07.2 Equivalency Review
07.3 Conformity Audit
08. Market Landscape
08.1 Market Overview
08.2 Market Size And Forecast
08.3 Five Forces Analysis
09. Market Segmentation By Product Category
10. Market Segmentation By Therapeutic Application
11. Buying Criteria
12. Market Growth Drivers
13. Drivers And Their Impact
14. Market Challenges
15. Impact Of Drivers And Challenges
16. Market Trends
17. Trends And Their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers And Acquisitions
18.2 Market Share Analysis 2014
18.3 Other Prominent Vendors
19. Key Vendor Analysis
19.1 Meiji Seika Pharma
19.1.1 Key Facts
19.1.2 Business Description
19.1.3 Business Segmentation
19.1.4 Business Strategy
19.1.5 Revenue By Business Segmentation
19.1.6 Revenue Comparison 2011 And 2012
19.1.7 Revenue By Geographical Segmentation
19.1.8 Key Information
19.1.9 Swot Analysis
19.2 Nichi-iko
19.2.1 Key Facts
19.2.2 Business Description
19.2.3 Business Segmentation
19.2.4 Business Strategy
19.2.5 Revenue By Business Segmentation
19.2.6 Revenue Comparison 2011 And 2012
19.2.7 Revenue By Geographical Segmentation
19.2.8 Key Information
19.2.9 Swot Analysis
19.3 Nipro Pharma
19.3.1 Key Facts
19.3.2 Business Description
19.3.3 Business Segmentation
19.3.4 Business Strategy
Generic Drugs Market in Japan 2015-2019
19.3.5 Revenue By Business Segmentation
19.3.6 Revenue Comparison 2011 And 2012
19.3.7 Revenue By Geographical Segmentation
19.3.8 Key Information
19.3.9 Swot Analysis
19.4 Sawai
19.4.1 Key Facts
19.4.2 Business Description
19.4.3 Business Segmentation
19.4.4 Business Strategy
19.4.5 Revenue By Business Segmentation
19.4.6 Revenue Comparison 2011 And 2012
19.4.7 Revenue By Geographical Segmentation
19.4.8 Key Information
19.4.9 Swot Analysis
19.5 Teva Pharmaceutical Industries
19.5.1 Key Facts
19.5.2 Business Description
19.5.3 Business Segmentation
19.5.4 Business Strategy
19.5.5 Revenue By Business Segmentation
19.5.6 Revenue Comparison 2011 And 2012
19.5.7 Revenue By Geographical Segmentation
19.5.8 Key Information
19.5.9 Swot Analysis
19.6 Towa Pharmaceutical
19.6.1 Key Facts
19.6.2 Business Description
19.6.3 Business Segmentation
19.6.4 Business Strategy
19.6.5 Revenue By Business Segmentation
19.6.6 Revenue Comparison 2011 And 2012
19.6.7 Revenue By Geographical Segmentation
19.6.8 Key Information
19.6.9 Swot Analysis
20. Other Reports In This Series
list Of Exhibits
exhibit 1: Market Research Methodology
exhibit 2: Country Overview Of Japan
exhibit 3: Main Data Required For Generic Drugs Approval
exhibit 4: Generic Drugs Market In Japan Overview
exhibit 5: Generic Drugs Market In Japan 2014-2019 (us$ Billion)
exhibit 6: Parameters To Promote The Use Of Generic Drugs Ahead
exhibit 7: Generic Drug Market Share Of Japan In 2014 (in Percent)
exhibit 8: Generic Drugs Market Share Of Japan In 2019 (in Percent)
exhibit 9: Generic Drugs Market Share Of Japan And Global (us$ Billion)
exhibit 10: Generic Drugs Market Segmentation By Product Category
exhibit 11: Generic Drugs Market In Japan By Therapeutic Applications
exhibit 12: Patent Expiration Of Branded Drugs In Japan
exhibit 13: Medical Costs In Japan (in Thousand Billion)
exhibit 14: Price Difference Of Atorvastatin Between Originator And Generic In Japan (us$)
exhibit 15: Trends Of Aging Population In Japan (in Percentage)
exhibit 16: Reviews Conducted For Generic Drugs And Others By Fiscal Year 2008-2012
exhibit 17: Comparison Between Applications Filed And Approval In Japan
exhibit 18: Meiji Seika Pharma: Business Segmentation By Revenue 2013
exhibit 19: Meiji Seika Pharma: Business Segmentation By Revenue 2012 And 2013 (us$ Million)
exhibit 20: Meiji Seika Pharma: Geographical Segmentation
exhibit 21: Nichi-iko: Business Segmentation By Revenue 2013
exhibit 22: Nichi-iko: Business Segmentation By Revenue 2012 And 2013
exhibit 23: Nichi-iko: Geographical Segmentation By Revenue 2013
exhibit 24: Nipro Pharma: Business Segmentation By Revenue 2013
exhibit 25: Nipro Pharma: Business Segmentation By Revenue 2012 And 2013
exhibit 26: Nipro Pharma: Geographical Segmentation By Revenue 2013
exhibit 27: Sawai: Business Segmentation By Revenue 2013
exhibit 28: Sawai: Business Segmentation By Revenue 2012 And 2013 (us$ Million)
exhibit 29: Sawai: Geographical Segmentation
exhibit 30: Teva Pharmaceutical Industries: Business Segmentation By Revenue 2013
Generic Drugs Market in Japan 2015-2019
exhibit 31: Teva Pharmaceutical Industries: Business Segmentation By Revenue 2012 And 2013
exhibit 32: Teva Pharmaceutical Industries: Geographical Segmentation By Revenue 2013
exhibit 33: Towa Pharmaceutical: Business Segmentation By Revenue 2013
exhibit 34: Towa Pharmaceutical: Business Segmentation By Revenue 2012 And 2013 (us$ Million)
exhibit 35: Towa Pharmaceutical: Geographical Segmentation
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
Sales Team,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Generic Drugs Market in Japan 2015-2019

Más contenido relacionado

Más de Ambikabasa

Rhabdomyosarcoma pipeline review, h1 2015
Rhabdomyosarcoma   pipeline review, h1 2015Rhabdomyosarcoma   pipeline review, h1 2015
Rhabdomyosarcoma pipeline review, h1 2015Ambikabasa
 
Raynauds disease pipeline review, h1 2015
Raynauds disease   pipeline review, h1 2015Raynauds disease   pipeline review, h1 2015
Raynauds disease pipeline review, h1 2015Ambikabasa
 
Travelers diarrhea pipeline review, h1 2015
Travelers diarrhea   pipeline review, h1 2015Travelers diarrhea   pipeline review, h1 2015
Travelers diarrhea pipeline review, h1 2015Ambikabasa
 
Herpes zoster (shingles) pipeline review, h1 2015
Herpes zoster (shingles)   pipeline review, h1 2015Herpes zoster (shingles)   pipeline review, h1 2015
Herpes zoster (shingles) pipeline review, h1 2015Ambikabasa
 
Emphysema pipeline review, h1 2015
Emphysema   pipeline review, h1 2015Emphysema   pipeline review, h1 2015
Emphysema pipeline review, h1 2015Ambikabasa
 
Cerebral infarction (brain infarction) pipeline review, h1 2015
Cerebral infarction (brain infarction)   pipeline review, h1 2015Cerebral infarction (brain infarction)   pipeline review, h1 2015
Cerebral infarction (brain infarction) pipeline review, h1 2015Ambikabasa
 
Seborrhea pipeline review, h1 2015
Seborrhea   pipeline review, h1 2015Seborrhea   pipeline review, h1 2015
Seborrhea pipeline review, h1 2015Ambikabasa
 
Respiratory depression pipeline review, h1 2015
Respiratory depression   pipeline review, h1 2015Respiratory depression   pipeline review, h1 2015
Respiratory depression pipeline review, h1 2015Ambikabasa
 
H1 n1 infection pipeline review, h1 2015
H1 n1 infection   pipeline review, h1 2015H1 n1 infection   pipeline review, h1 2015
H1 n1 infection pipeline review, h1 2015Ambikabasa
 
Nicotine addiction pipeline review, h1 2015
Nicotine addiction   pipeline review, h1 2015Nicotine addiction   pipeline review, h1 2015
Nicotine addiction pipeline review, h1 2015Ambikabasa
 
Food allergy pipeline review, h1 2015
Food allergy   pipeline review, h1 2015Food allergy   pipeline review, h1 2015
Food allergy pipeline review, h1 2015Ambikabasa
 
Uveal melanoma pipeline review, h1 2015
Uveal melanoma   pipeline review, h1 2015Uveal melanoma   pipeline review, h1 2015
Uveal melanoma pipeline review, h1 2015Ambikabasa
 
Tillotts pharma ag product pipeline review - 2015
Tillotts pharma ag   product pipeline review - 2015Tillotts pharma ag   product pipeline review - 2015
Tillotts pharma ag product pipeline review - 2015Ambikabasa
 
Co mentis, inc. product pipeline review - 2015
Co mentis, inc.   product pipeline review - 2015Co mentis, inc.   product pipeline review - 2015
Co mentis, inc. product pipeline review - 2015Ambikabasa
 
Therapure biopharma inc. product pipeline review - 2015
Therapure biopharma inc.   product pipeline review - 2015Therapure biopharma inc.   product pipeline review - 2015
Therapure biopharma inc. product pipeline review - 2015Ambikabasa
 
Genzyme corporation product pipeline review - 2015
Genzyme corporation   product pipeline review - 2015Genzyme corporation   product pipeline review - 2015
Genzyme corporation product pipeline review - 2015Ambikabasa
 
Quantum genomics sa product pipeline review - 2015
Quantum genomics sa   product pipeline review - 2015Quantum genomics sa   product pipeline review - 2015
Quantum genomics sa product pipeline review - 2015Ambikabasa
 
Brain cancer pipeline review, h1 2015
Brain cancer   pipeline review, h1 2015Brain cancer   pipeline review, h1 2015
Brain cancer pipeline review, h1 2015Ambikabasa
 
Diarrhea pipeline review, h1 2015
Diarrhea   pipeline review, h1 2015Diarrhea   pipeline review, h1 2015
Diarrhea pipeline review, h1 2015Ambikabasa
 
Integra gen s.a (alint) product pipeline analysis, 2014 update
Integra gen s.a (alint)   product pipeline analysis, 2014 updateIntegra gen s.a (alint)   product pipeline analysis, 2014 update
Integra gen s.a (alint) product pipeline analysis, 2014 updateAmbikabasa
 

Más de Ambikabasa (20)

Rhabdomyosarcoma pipeline review, h1 2015
Rhabdomyosarcoma   pipeline review, h1 2015Rhabdomyosarcoma   pipeline review, h1 2015
Rhabdomyosarcoma pipeline review, h1 2015
 
Raynauds disease pipeline review, h1 2015
Raynauds disease   pipeline review, h1 2015Raynauds disease   pipeline review, h1 2015
Raynauds disease pipeline review, h1 2015
 
Travelers diarrhea pipeline review, h1 2015
Travelers diarrhea   pipeline review, h1 2015Travelers diarrhea   pipeline review, h1 2015
Travelers diarrhea pipeline review, h1 2015
 
Herpes zoster (shingles) pipeline review, h1 2015
Herpes zoster (shingles)   pipeline review, h1 2015Herpes zoster (shingles)   pipeline review, h1 2015
Herpes zoster (shingles) pipeline review, h1 2015
 
Emphysema pipeline review, h1 2015
Emphysema   pipeline review, h1 2015Emphysema   pipeline review, h1 2015
Emphysema pipeline review, h1 2015
 
Cerebral infarction (brain infarction) pipeline review, h1 2015
Cerebral infarction (brain infarction)   pipeline review, h1 2015Cerebral infarction (brain infarction)   pipeline review, h1 2015
Cerebral infarction (brain infarction) pipeline review, h1 2015
 
Seborrhea pipeline review, h1 2015
Seborrhea   pipeline review, h1 2015Seborrhea   pipeline review, h1 2015
Seborrhea pipeline review, h1 2015
 
Respiratory depression pipeline review, h1 2015
Respiratory depression   pipeline review, h1 2015Respiratory depression   pipeline review, h1 2015
Respiratory depression pipeline review, h1 2015
 
H1 n1 infection pipeline review, h1 2015
H1 n1 infection   pipeline review, h1 2015H1 n1 infection   pipeline review, h1 2015
H1 n1 infection pipeline review, h1 2015
 
Nicotine addiction pipeline review, h1 2015
Nicotine addiction   pipeline review, h1 2015Nicotine addiction   pipeline review, h1 2015
Nicotine addiction pipeline review, h1 2015
 
Food allergy pipeline review, h1 2015
Food allergy   pipeline review, h1 2015Food allergy   pipeline review, h1 2015
Food allergy pipeline review, h1 2015
 
Uveal melanoma pipeline review, h1 2015
Uveal melanoma   pipeline review, h1 2015Uveal melanoma   pipeline review, h1 2015
Uveal melanoma pipeline review, h1 2015
 
Tillotts pharma ag product pipeline review - 2015
Tillotts pharma ag   product pipeline review - 2015Tillotts pharma ag   product pipeline review - 2015
Tillotts pharma ag product pipeline review - 2015
 
Co mentis, inc. product pipeline review - 2015
Co mentis, inc.   product pipeline review - 2015Co mentis, inc.   product pipeline review - 2015
Co mentis, inc. product pipeline review - 2015
 
Therapure biopharma inc. product pipeline review - 2015
Therapure biopharma inc.   product pipeline review - 2015Therapure biopharma inc.   product pipeline review - 2015
Therapure biopharma inc. product pipeline review - 2015
 
Genzyme corporation product pipeline review - 2015
Genzyme corporation   product pipeline review - 2015Genzyme corporation   product pipeline review - 2015
Genzyme corporation product pipeline review - 2015
 
Quantum genomics sa product pipeline review - 2015
Quantum genomics sa   product pipeline review - 2015Quantum genomics sa   product pipeline review - 2015
Quantum genomics sa product pipeline review - 2015
 
Brain cancer pipeline review, h1 2015
Brain cancer   pipeline review, h1 2015Brain cancer   pipeline review, h1 2015
Brain cancer pipeline review, h1 2015
 
Diarrhea pipeline review, h1 2015
Diarrhea   pipeline review, h1 2015Diarrhea   pipeline review, h1 2015
Diarrhea pipeline review, h1 2015
 
Integra gen s.a (alint) product pipeline analysis, 2014 update
Integra gen s.a (alint)   product pipeline analysis, 2014 updateIntegra gen s.a (alint)   product pipeline analysis, 2014 update
Integra gen s.a (alint) product pipeline analysis, 2014 update
 

Último

FULL ENJOY Call girls in Paharganj Delhi | 8377087607
FULL ENJOY Call girls in Paharganj Delhi | 8377087607FULL ENJOY Call girls in Paharganj Delhi | 8377087607
FULL ENJOY Call girls in Paharganj Delhi | 8377087607dollysharma2066
 
8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR
8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR
8447779800, Low rate Call girls in New Ashok Nagar Delhi NCRashishs7044
 
Case study on tata clothing brand zudio in detail
Case study on tata clothing brand zudio in detailCase study on tata clothing brand zudio in detail
Case study on tata clothing brand zudio in detailAriel592675
 
Intro to BCG's Carbon Emissions Benchmark_vF.pdf
Intro to BCG's Carbon Emissions Benchmark_vF.pdfIntro to BCG's Carbon Emissions Benchmark_vF.pdf
Intro to BCG's Carbon Emissions Benchmark_vF.pdfpollardmorgan
 
Traction part 2 - EOS Model JAX Bridges.
Traction part 2 - EOS Model JAX Bridges.Traction part 2 - EOS Model JAX Bridges.
Traction part 2 - EOS Model JAX Bridges.Anamaria Contreras
 
Digital Transformation in the PLM domain - distrib.pdf
Digital Transformation in the PLM domain - distrib.pdfDigital Transformation in the PLM domain - distrib.pdf
Digital Transformation in the PLM domain - distrib.pdfJos Voskuil
 
Youth Involvement in an Innovative Coconut Value Chain by Mwalimu Menza
Youth Involvement in an Innovative Coconut Value Chain by Mwalimu MenzaYouth Involvement in an Innovative Coconut Value Chain by Mwalimu Menza
Youth Involvement in an Innovative Coconut Value Chain by Mwalimu Menzaictsugar
 
Global Scenario On Sustainable and Resilient Coconut Industry by Dr. Jelfina...
Global Scenario On Sustainable  and Resilient Coconut Industry by Dr. Jelfina...Global Scenario On Sustainable  and Resilient Coconut Industry by Dr. Jelfina...
Global Scenario On Sustainable and Resilient Coconut Industry by Dr. Jelfina...ictsugar
 
Kenya Coconut Production Presentation by Dr. Lalith Perera
Kenya Coconut Production Presentation by Dr. Lalith PereraKenya Coconut Production Presentation by Dr. Lalith Perera
Kenya Coconut Production Presentation by Dr. Lalith Pereraictsugar
 
Market Sizes Sample Report - 2024 Edition
Market Sizes Sample Report - 2024 EditionMarket Sizes Sample Report - 2024 Edition
Market Sizes Sample Report - 2024 EditionMintel Group
 
Call Girls in DELHI Cantt, ( Call Me )-8377877756-Female Escort- In Delhi / Ncr
Call Girls in DELHI Cantt, ( Call Me )-8377877756-Female Escort- In Delhi / NcrCall Girls in DELHI Cantt, ( Call Me )-8377877756-Female Escort- In Delhi / Ncr
Call Girls in DELHI Cantt, ( Call Me )-8377877756-Female Escort- In Delhi / Ncrdollysharma2066
 
Ten Organizational Design Models to align structure and operations to busines...
Ten Organizational Design Models to align structure and operations to busines...Ten Organizational Design Models to align structure and operations to busines...
Ten Organizational Design Models to align structure and operations to busines...Seta Wicaksana
 
Independent Call Girls Andheri Nightlaila 9967584737
Independent Call Girls Andheri Nightlaila 9967584737Independent Call Girls Andheri Nightlaila 9967584737
Independent Call Girls Andheri Nightlaila 9967584737Riya Pathan
 
Islamabad Escorts | Call 03070433345 | Escort Service in Islamabad
Islamabad Escorts | Call 03070433345 | Escort Service in IslamabadIslamabad Escorts | Call 03070433345 | Escort Service in Islamabad
Islamabad Escorts | Call 03070433345 | Escort Service in IslamabadAyesha Khan
 
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCRashishs7044
 
8447779800, Low rate Call girls in Saket Delhi NCR
8447779800, Low rate Call girls in Saket Delhi NCR8447779800, Low rate Call girls in Saket Delhi NCR
8447779800, Low rate Call girls in Saket Delhi NCRashishs7044
 
Contemporary Economic Issues Facing the Filipino Entrepreneur (1).pptx
Contemporary Economic Issues Facing the Filipino Entrepreneur (1).pptxContemporary Economic Issues Facing the Filipino Entrepreneur (1).pptx
Contemporary Economic Issues Facing the Filipino Entrepreneur (1).pptxMarkAnthonyAurellano
 
MAHA Global and IPR: Do Actions Speak Louder Than Words?
MAHA Global and IPR: Do Actions Speak Louder Than Words?MAHA Global and IPR: Do Actions Speak Louder Than Words?
MAHA Global and IPR: Do Actions Speak Louder Than Words?Olivia Kresic
 
IoT Insurance Observatory: summary 2024
IoT Insurance Observatory:  summary 2024IoT Insurance Observatory:  summary 2024
IoT Insurance Observatory: summary 2024Matteo Carbone
 

Último (20)

FULL ENJOY Call girls in Paharganj Delhi | 8377087607
FULL ENJOY Call girls in Paharganj Delhi | 8377087607FULL ENJOY Call girls in Paharganj Delhi | 8377087607
FULL ENJOY Call girls in Paharganj Delhi | 8377087607
 
8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR
8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR
8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR
 
Case study on tata clothing brand zudio in detail
Case study on tata clothing brand zudio in detailCase study on tata clothing brand zudio in detail
Case study on tata clothing brand zudio in detail
 
Intro to BCG's Carbon Emissions Benchmark_vF.pdf
Intro to BCG's Carbon Emissions Benchmark_vF.pdfIntro to BCG's Carbon Emissions Benchmark_vF.pdf
Intro to BCG's Carbon Emissions Benchmark_vF.pdf
 
Traction part 2 - EOS Model JAX Bridges.
Traction part 2 - EOS Model JAX Bridges.Traction part 2 - EOS Model JAX Bridges.
Traction part 2 - EOS Model JAX Bridges.
 
Corporate Profile 47Billion Information Technology
Corporate Profile 47Billion Information TechnologyCorporate Profile 47Billion Information Technology
Corporate Profile 47Billion Information Technology
 
Digital Transformation in the PLM domain - distrib.pdf
Digital Transformation in the PLM domain - distrib.pdfDigital Transformation in the PLM domain - distrib.pdf
Digital Transformation in the PLM domain - distrib.pdf
 
Youth Involvement in an Innovative Coconut Value Chain by Mwalimu Menza
Youth Involvement in an Innovative Coconut Value Chain by Mwalimu MenzaYouth Involvement in an Innovative Coconut Value Chain by Mwalimu Menza
Youth Involvement in an Innovative Coconut Value Chain by Mwalimu Menza
 
Global Scenario On Sustainable and Resilient Coconut Industry by Dr. Jelfina...
Global Scenario On Sustainable  and Resilient Coconut Industry by Dr. Jelfina...Global Scenario On Sustainable  and Resilient Coconut Industry by Dr. Jelfina...
Global Scenario On Sustainable and Resilient Coconut Industry by Dr. Jelfina...
 
Kenya Coconut Production Presentation by Dr. Lalith Perera
Kenya Coconut Production Presentation by Dr. Lalith PereraKenya Coconut Production Presentation by Dr. Lalith Perera
Kenya Coconut Production Presentation by Dr. Lalith Perera
 
Market Sizes Sample Report - 2024 Edition
Market Sizes Sample Report - 2024 EditionMarket Sizes Sample Report - 2024 Edition
Market Sizes Sample Report - 2024 Edition
 
Call Girls in DELHI Cantt, ( Call Me )-8377877756-Female Escort- In Delhi / Ncr
Call Girls in DELHI Cantt, ( Call Me )-8377877756-Female Escort- In Delhi / NcrCall Girls in DELHI Cantt, ( Call Me )-8377877756-Female Escort- In Delhi / Ncr
Call Girls in DELHI Cantt, ( Call Me )-8377877756-Female Escort- In Delhi / Ncr
 
Ten Organizational Design Models to align structure and operations to busines...
Ten Organizational Design Models to align structure and operations to busines...Ten Organizational Design Models to align structure and operations to busines...
Ten Organizational Design Models to align structure and operations to busines...
 
Independent Call Girls Andheri Nightlaila 9967584737
Independent Call Girls Andheri Nightlaila 9967584737Independent Call Girls Andheri Nightlaila 9967584737
Independent Call Girls Andheri Nightlaila 9967584737
 
Islamabad Escorts | Call 03070433345 | Escort Service in Islamabad
Islamabad Escorts | Call 03070433345 | Escort Service in IslamabadIslamabad Escorts | Call 03070433345 | Escort Service in Islamabad
Islamabad Escorts | Call 03070433345 | Escort Service in Islamabad
 
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR
 
8447779800, Low rate Call girls in Saket Delhi NCR
8447779800, Low rate Call girls in Saket Delhi NCR8447779800, Low rate Call girls in Saket Delhi NCR
8447779800, Low rate Call girls in Saket Delhi NCR
 
Contemporary Economic Issues Facing the Filipino Entrepreneur (1).pptx
Contemporary Economic Issues Facing the Filipino Entrepreneur (1).pptxContemporary Economic Issues Facing the Filipino Entrepreneur (1).pptx
Contemporary Economic Issues Facing the Filipino Entrepreneur (1).pptx
 
MAHA Global and IPR: Do Actions Speak Louder Than Words?
MAHA Global and IPR: Do Actions Speak Louder Than Words?MAHA Global and IPR: Do Actions Speak Louder Than Words?
MAHA Global and IPR: Do Actions Speak Louder Than Words?
 
IoT Insurance Observatory: summary 2024
IoT Insurance Observatory:  summary 2024IoT Insurance Observatory:  summary 2024
IoT Insurance Observatory: summary 2024
 

Generic drugs market in japan 2015 2019

  • 1. Generic Drugs Market in Japan 2015-2019 About Generic Drugs A generic drug is a duplicate of brand-name drugs and has the same dosage form, active ingredient(s), potency, route of administration, quality, and intended use as that of branded drugs. Generic drugs enter the market once the patent protection of the original developer expires. Generally, the cost of generic drugs is 50-70 percent lower than that of their brand-name counterparts, while meeting the very same standards of safety, quality, and efficacy as the innovator drugs. Generic drugs help the manufacturer by eliminating the need to develop and market a new drug. As the patent approaches expiration, manufacturers can apply to the FDA for approval to manufacture and sell generic versions of the drug. Generic drugs are equal to and within the bioequivalence range of branded drugs. TechNavio's analysts forecast the Generic Drugs market in Japan to grow at a CAGR of 8.16 percent over the period 2014-2019. Covered in this Report The Generic Drugs market in Japan can be divided into three segments: Generic Prescription Medicines, Super Generics, and Biosimilars. This report covers the present scenario and the growth prospects of the Generic Drugs market in Japan for the period 20152019. To calculate the market size, the report considers the revenue generated from the following segments: Generic Prescription Medicines Super Generics Biosimilars TechNavio's report, the Generic Drugs market in Japan 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape of the Generic Drugs market in Japan and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors Meiji Seika Pharma Nichi-Iko Pharmaceutical Nipro Pharma Sawai Pharmaceuticals Teva Pharmaceutical Industries Towa Pharmaceutical Other Prominent Vendors Actavis Daiichi Sankyo Daito Pharmaceutical Eisai Fuji Pharma GlaxoSmithKline Hikari Pharmaceutical Hospira Mylan Nihon Generic Nippon Chemipher Nippon Kayaku Nissin Pharmaceutical Ohara Pharmaceutical Pfizer Sandoz Taiyo Yakuhin Takeda Pharmaceutical Zensei Pharmaceutical Industries Market Driver Increase in Number of Patent Expiries For a full, detailed list, view our report. Market Challenge Intense Competition among Vendors For a full, detailed list, view our report Market Trend Increase in M&A For a full, detailed list, view our report Key Questions Answered in this Report Generic Drugs Market in Japan 2015-2019
  • 2. What will the market size be in 2019 and what will the growth rate be? What are the key market trends? What is driving this market? What are the challenges to market growth? Who are the key vendors in this market space? What are the market opportunities and threats faced by the key vendors? What are the strengths and weaknesses of the key vendors? 01. Executive Summary 02. List Of Abbreviations 03. Scope Of The Report 03.1 Market Overview 03.2 Product Offerings 04. Market Research Methodology 04.1 Market Research Process 04.2 Research Methodology 05. Introduction 06. Country Overview Of Japan 07. Approval Pathway Of Generic Drugs In Japan 07.1 Master File Scheme For Active Ingredients 07.2 Equivalency Review 07.3 Conformity Audit 08. Market Landscape 08.1 Market Overview 08.2 Market Size And Forecast 08.3 Five Forces Analysis 09. Market Segmentation By Product Category 10. Market Segmentation By Therapeutic Application 11. Buying Criteria 12. Market Growth Drivers 13. Drivers And Their Impact 14. Market Challenges 15. Impact Of Drivers And Challenges 16. Market Trends 17. Trends And Their Impact 18. Vendor Landscape 18.1 Competitive Scenario 18.1.1 Key News 18.1.2 Mergers And Acquisitions 18.2 Market Share Analysis 2014 18.3 Other Prominent Vendors 19. Key Vendor Analysis 19.1 Meiji Seika Pharma 19.1.1 Key Facts 19.1.2 Business Description 19.1.3 Business Segmentation 19.1.4 Business Strategy 19.1.5 Revenue By Business Segmentation 19.1.6 Revenue Comparison 2011 And 2012 19.1.7 Revenue By Geographical Segmentation 19.1.8 Key Information 19.1.9 Swot Analysis 19.2 Nichi-iko 19.2.1 Key Facts 19.2.2 Business Description 19.2.3 Business Segmentation 19.2.4 Business Strategy 19.2.5 Revenue By Business Segmentation 19.2.6 Revenue Comparison 2011 And 2012 19.2.7 Revenue By Geographical Segmentation 19.2.8 Key Information 19.2.9 Swot Analysis 19.3 Nipro Pharma 19.3.1 Key Facts 19.3.2 Business Description 19.3.3 Business Segmentation 19.3.4 Business Strategy Generic Drugs Market in Japan 2015-2019
  • 3. 19.3.5 Revenue By Business Segmentation 19.3.6 Revenue Comparison 2011 And 2012 19.3.7 Revenue By Geographical Segmentation 19.3.8 Key Information 19.3.9 Swot Analysis 19.4 Sawai 19.4.1 Key Facts 19.4.2 Business Description 19.4.3 Business Segmentation 19.4.4 Business Strategy 19.4.5 Revenue By Business Segmentation 19.4.6 Revenue Comparison 2011 And 2012 19.4.7 Revenue By Geographical Segmentation 19.4.8 Key Information 19.4.9 Swot Analysis 19.5 Teva Pharmaceutical Industries 19.5.1 Key Facts 19.5.2 Business Description 19.5.3 Business Segmentation 19.5.4 Business Strategy 19.5.5 Revenue By Business Segmentation 19.5.6 Revenue Comparison 2011 And 2012 19.5.7 Revenue By Geographical Segmentation 19.5.8 Key Information 19.5.9 Swot Analysis 19.6 Towa Pharmaceutical 19.6.1 Key Facts 19.6.2 Business Description 19.6.3 Business Segmentation 19.6.4 Business Strategy 19.6.5 Revenue By Business Segmentation 19.6.6 Revenue Comparison 2011 And 2012 19.6.7 Revenue By Geographical Segmentation 19.6.8 Key Information 19.6.9 Swot Analysis 20. Other Reports In This Series list Of Exhibits exhibit 1: Market Research Methodology exhibit 2: Country Overview Of Japan exhibit 3: Main Data Required For Generic Drugs Approval exhibit 4: Generic Drugs Market In Japan Overview exhibit 5: Generic Drugs Market In Japan 2014-2019 (us$ Billion) exhibit 6: Parameters To Promote The Use Of Generic Drugs Ahead exhibit 7: Generic Drug Market Share Of Japan In 2014 (in Percent) exhibit 8: Generic Drugs Market Share Of Japan In 2019 (in Percent) exhibit 9: Generic Drugs Market Share Of Japan And Global (us$ Billion) exhibit 10: Generic Drugs Market Segmentation By Product Category exhibit 11: Generic Drugs Market In Japan By Therapeutic Applications exhibit 12: Patent Expiration Of Branded Drugs In Japan exhibit 13: Medical Costs In Japan (in Thousand Billion) exhibit 14: Price Difference Of Atorvastatin Between Originator And Generic In Japan (us$) exhibit 15: Trends Of Aging Population In Japan (in Percentage) exhibit 16: Reviews Conducted For Generic Drugs And Others By Fiscal Year 2008-2012 exhibit 17: Comparison Between Applications Filed And Approval In Japan exhibit 18: Meiji Seika Pharma: Business Segmentation By Revenue 2013 exhibit 19: Meiji Seika Pharma: Business Segmentation By Revenue 2012 And 2013 (us$ Million) exhibit 20: Meiji Seika Pharma: Geographical Segmentation exhibit 21: Nichi-iko: Business Segmentation By Revenue 2013 exhibit 22: Nichi-iko: Business Segmentation By Revenue 2012 And 2013 exhibit 23: Nichi-iko: Geographical Segmentation By Revenue 2013 exhibit 24: Nipro Pharma: Business Segmentation By Revenue 2013 exhibit 25: Nipro Pharma: Business Segmentation By Revenue 2012 And 2013 exhibit 26: Nipro Pharma: Geographical Segmentation By Revenue 2013 exhibit 27: Sawai: Business Segmentation By Revenue 2013 exhibit 28: Sawai: Business Segmentation By Revenue 2012 And 2013 (us$ Million) exhibit 29: Sawai: Geographical Segmentation exhibit 30: Teva Pharmaceutical Industries: Business Segmentation By Revenue 2013 Generic Drugs Market in Japan 2015-2019
  • 4. exhibit 31: Teva Pharmaceutical Industries: Business Segmentation By Revenue 2012 And 2013 exhibit 32: Teva Pharmaceutical Industries: Geographical Segmentation By Revenue 2013 exhibit 33: Towa Pharmaceutical: Business Segmentation By Revenue 2013 exhibit 34: Towa Pharmaceutical: Business Segmentation By Revenue 2012 And 2013 (us$ Million) exhibit 35: Towa Pharmaceutical: Geographical Segmentation ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: Sales Team, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Generic Drugs Market in Japan 2015-2019